FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2016 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, chief executive officer, will present at the 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016, at 2:55 PM Eastern Time. The conference is being held at the Westin Waterfront Hotel in Boston.
To access the live webcast of MyoKardia’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the MyoKardia website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 30 days following the conference.
About MyoKardia
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM and is currently being evaluated in three Phase 1 clinical trials. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of data from approximately 10,000 individuals, is the world’s largest registry of patients with heritable cardiomyopathies. MyoKardia’s purpose is to improve the lives of patients and families suffering from cardiovascular disease by creating targeted therapies that can change the course of their condition. For more information, please visit www.myokardia.com.
Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. 212-362-1200 [email protected] Media Contact: Steven Cooper Edelman 415-486-3264 [email protected]
